Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2020

01-09-2020 | Sarcoma | Review Article

Precision medicine in Ewing sarcoma: a translational point of view

Authors: P. Gargallo, A. Juan, Y. Yáñez, S. Dolz, V. Segura, V. Castel, A. Cañete

Published in: Clinical and Translational Oncology | Issue 9/2020

Login to get access

Abstract

Ewing sarcoma is a rare tumor that arises in bones of children and teenagers but, in 15% of the patients it is presented as a primary soft tissue tumor. Balanced reciprocal chimeric translocation t(11;22)(q24;q12), which encodes an oncogenic protein fusion (EWSR1/FLI1), is the most generalized and characteristic molecular event. Using conventional treatments, (chemotherapy, surgery and radiotherapy) long-term overall survival rate is 30% for patients with disseminated disease and 65–75% for patients with localized tumors. Urgent new effective drug development is a challenge. This review summarizes the preclinical and clinical investigational knowledge about prognostic and targetable biomarkers in Ewing sarcoma, finally suggesting a workflow for precision medicine committees.
Literature
1.
Choi EY, Gardner JM, Lucas DR, McHugh JB, Patel RM. Ewing sarcoma. Semin Diagn Pathol. 2014;31(1):39–47.PubMed
2.
Fletcher C, Bridge J, Hogendoorn P, Mertens F. Classification of tumours pathology and genetics of tumours of soft tissue and bone. In World Health Organization, 4thEd (Lyon: IARC Press); 2013: 306–309.
3.
Savita S, Stephen L. Promiscuous Partnerships in Ewing’s Sarcoma. Cancer Genet. 2011;204(7):351–65.
4.
Horowitz M, Malawer M, Woo S, et al. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. Pizzo, PA.; Poplack, DG. (eds) Principles and practice of pediatric oncology. Philadelphia: Lippincott-Raven Publishers; 1997. p. 831–863.
5.
Kimber C, Michalski A, Spitz L, Pierro A. Primitive neuroectodermal tumours: anatomic location, extentof surgery, and outcome. J Pediatr Surg. 1998;33:39–41.PubMed
6.
Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol. 2015;33(27):3036–46.PubMed
7.
Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N, Committee COGBT. Children’s Oncology Group’s 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013;60:1009–155.PubMed
8.
Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle. 2008;7:250–6.PubMed
9.
Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 2013;32:5089–100.PubMed
10.
Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol. 2012;7:145–59.PubMed
11.
Takigami I, Ohno T, Kitade Y, Hara A, Nagano A, Kawai G, et al. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int J Cancer. 2011;128:216–26.PubMed
12.
Maksimenko A, Malvy C. Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin Ther Targets. 2005;9:825–30.PubMed
13.
Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, Notario V. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res. 2006;12:6781–90.PubMed
14.
Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, et al. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res. 2013;41(19):8853–71.PubMedPubMedCentral
15.
Riggi N, Knoechel B, Shawn M, Rheinbay E, Boulay G, Suvà M, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668–81.PubMedPubMedCentral
16.
Hattinger CM, Pötschger U, Tarkkanen M, Squire J, Zielenska M, Kiuru-Kuhlefelt S, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer. 2002;86:1763–9.PubMedPubMedCentral
17.
Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2012;31:1287–98.PubMed
18.
Roberts P, Burchill SA, Brownhill S, Cullinane CJ, Johnston C, Griffiths MJ, et al. Ploidy and karyotype complexity are powerful prognostic indicators in the Ewingʼs sarcoma family of tumors: A study by the united kingdom cancer cytogenetics and the childrenʼs cancer and leukaemia group. Genes Chromosomes Cancer. 2008;47:207–20.PubMed
19.
Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73.PubMed
20.
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10(7):e1004475.PubMedPubMedCentral
21.
Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314:913–25.PubMedPubMedCentral
22.
Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) study. JAMA Oncol. 2016;2:608–15.PubMed
23.
Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, et al. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016;8:133.PubMedPubMedCentral
24.
Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2:616–24.PubMedPubMedCentral
25.
Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generation personalised medicine for high-risk paediatric cancer patients the INFORM pilot study. Eur J Cancer. 2016;65:91–101.PubMed
26.
Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, et al. MOlecular Screening for CAncerTreatment Optimization (MOSCATO-01) in pediatric patients: a single institutional prospective molecular stratification trial. Clin Cancer Res. 2017;23:6101–12.PubMed
27.
Pincez T, Clement N, Lapouble E, Pierron G, Kamal M, Bieche I, et al. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer. 2017;64:e26365.
28.
Glade Bender J, Verma A, Schiffman JD. Translating genomic discoveries to the clinic in pediatric oncology. Curr Opin Pediatr. 2015;27(1):34–433.PubMed
29.
Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108–14.PubMed
30.
Rodríguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008;19(4):814–20.PubMed
31.
Sauer R, Jurgens H, Burgers JM, Dunst J, Hawlicek R, Michaelis J. Prognostic factors in the treatment of Ewing’ssarcoma The Ewing’s Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol. 1987;10:101–10.PubMed
32.
Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population based cancer registry. Cancer. 2010;116:1964–73.PubMed
33.
Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63(10):1771–9.PubMedPubMedCentral
34.
Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol. 2003;40:141–7.PubMed
35.
Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing’s sarcoma. J Clin Oncol. 2005;23:4354–62.PubMed
36.
De Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol. 1998;16:1248–55.PubMed
37.
Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol. 1996;14:1245–51.PubMed
38.
Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, et al. Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro- EWING 99 trial. J Clin Oncol. 2010;28:1982–8.PubMed
39.
Barr FG, Meyer WH. Role of fusion subtype in Ewing sarcoma. J Clin Oncol. 2010;28:1973–4.PubMed
40.
Van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, et al. Current treatment protocol shave eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28:1989–94.PubMedPubMedCentral
41.
Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, et al. Combined use of expression and cgh arrays pin points novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer. 2009;9:17.PubMedPubMedCentral
42.
Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O, et al. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet Cytogenet. 2001;130(1):57–61.PubMed
43.
Sannino G, Orth M, Grünewald T. Next steps in Ewing sarcoma (epi-) Genomics. Future Oncol. 2017;13(14):1207–11.PubMed
44.
Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is fre quently lost in the Ewing family of tumors. Oncogene. 1997;15:2225–32.PubMed
45.
Brownhill SC, Taylor C, Burchill SA. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer. 2007;96:1914–23.PubMedPubMedCentral
46.
Wei G, Antonescu CR, De Alava E, Leung D, Huvos AG, Meyers PA, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer. 2000;89:793–9.PubMed
47.
Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16 INK4, p14 ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120:91–8.PubMed
48.
Maitra A, Roberts H, Weinberg AG, Geradts J. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med. 2001;125:1207–12.PubMed
49.
Honoki K, Stojanovski E, Mcevoy M, Fujii H, Tsujiuchi T, Kido A, et al. Prognostic significance of p16 INK4 alteration for Ewing sarcoma:a meta-analysis. Cancer. 2007;110:1351–60.PubMed
50.
Shukla N, Schiffman JD, Reed D, Davis IJ, Womer RB, Lessnick SL, et al. Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine A report from the Children’s Oncology Group. Front Oncol. 2013;3:141.PubMedPubMedCentral
51.
Lerman DM, Monument MJ, McIlvaine E, Liu X, Huang ML, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the children’s oncology group. Pediatr Blood Cancer. 2015;62(5):759–65.PubMed
52.
Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of stag2 and tp53 mutations. Cancer Discov. 2014;4:1342–53.PubMedPubMedCentral
53.
Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, et al. Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer. 1999;79:1185–9.PubMedPubMedCentral
54.
de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer. 2000;89:783–92.PubMed
55.
Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14 ARF homozygous deletion: a highly lethal subset associated with poor chemo response. J Clin Oncol. 2005;23:548–58.PubMed
56.
Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing’s sarcoma family of tumors. Int J Cancer. 2011;128:1139–50.PubMed
57.
Crompton BD, Stewart C, Taylor-Weiner A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326–41.PubMed
58.
Alholle A, Brini AT, Gharanei S, Vaiyapuri S, Arrigoni E, Dallo A, et al. Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma. Epigenetics. 2013;8(11):1198–204.PubMed
59.
Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallo A, Arrigoni E, et al. RASSF2 methylation is a strong prognostic markerin younger age patients with Ewing sarcoma. Epigenetics. 2013;8(9):893–8.PubMedPubMedCentral
60.
Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol Chem. 2003;278:28045–51.PubMed
61.
Donninger H, Hesson L, Vos M, Beebe K, Gordon L, Sidransky D, et al. The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Molec Cell Biol. 2010;30:2608–20.PubMed
62.
Sand LG, Berghuis D, Szuhai K, Hogendoorn PC. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy. Cancer Immunol Immunother. 2016;65:995–1002.PubMedPubMedCentral
63.
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE. 2013;8(12):e82870.PubMedPubMedCentral
64.
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–5.PubMed
65.
May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci. 1993;90:5752–6.PubMed
66.
Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1 dependent, Ewing sarcoma-like tumors. Cancer Res. 2005;65:8698–705.PubMed
67.
Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, et al. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005;65:11459–68.PubMed
68.
Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells. J Clin Invest. 1997;99:239–47.PubMedPubMedCentral
69.
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res. 2005;65:8984–92.PubMed
70.
Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, et al. Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer. 2009;101:80–90.PubMedPubMedCentral
71.
Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 2013;23:1797–809.PubMedPubMedCentral
72.
Gangwal K, Close D, Enriquez CA, Hill CP, Lessnick SL. Emergent properties of EWS/FLI regulation via GGAA microsatellites in Ewing's sarcoma. Genes Cancer. 2010;1:177–87.PubMedPubMedCentral
73.
Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA. 2008;105:10149–54.PubMed
74.
Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS ONE. 2009;4:e4932.PubMedPubMedCentral
75.
Patel M, Simon JM, Iglesia MD, Wu SB, McFadden AW, Lieb JD, Davis IJ. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome Res. 2012;22:259–70.PubMedPubMedCentral
76.
Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, et al. Oncoprotein EWS-FLI1 Activity Is Enhanced by RNA Helicase A. Cancer Res. 2006;66(11):5574–81.PubMed
77.
Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, et al. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget. 2014;5(2):338–50.PubMed
78.
Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc Natl Acad Sci USA. 2015;112(11):E1307–E13161316.PubMed
79.
Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15(7):750–6.PubMedPubMedCentral
80.
Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Aiyer RA, Maywald RL, Buford AS, et al. An oral formulation of YK-4-279: preclinical efficacy and acquired resistance patterns in Ewing sarcoma. Mol Cancer Ther. 2015;14(7):1591–604.PubMed
81.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002;298:1039–43.PubMed
82.
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genet. 2010;42:722–6.PubMed
83.
Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endotelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA. 2009;106(13):5324–9.PubMed
84.
Ciarapica R, Miele L, Giordano A, Locatelli F. Rota R Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Med. 2011;9:63.PubMedPubMedCentral
85.
Pandya PH, Bailey B, Elmi AE, Bates HB, Hemenway CN, Sinn AL, et al. Preclinical validation of EZH2 as a therapeutic target in pediatric Ewing's sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; Cancer Res. 2018; 78(13 Suppl): Abstract nr 3180.
86.
Ramaglia M, D'Angelo V, Iannotta A, Di Pinto D, Pota E, Affinita MC, et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int. 2016;16:59.PubMedPubMedCentral
87.
Maruyama T, Farina A, Dey A, Cheong J, Bermudez VP, Tamura T, et al. A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase. Mol Cell Biol. 2002;22:6509–20.PubMedPubMedCentral
88.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLLfusion leukaemia. Nature. 2011;478:529–33.PubMedPubMedCentral
89.
Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, et al. Targeting the EWS-ETS transcriptional program by BET. Oncotarget. 2016;7(2):1451–63.PubMed
90.
Shao GB, Chen JC, Zhang LP, Huang P, Lu HY, Jin J, et al. Dynamic patterns of histone H3 lysine 4 methyltransferases and demethylases during mouse preimplantation development. In Vitro Cell Dev Biol Anim. 2014;50:603–13.PubMed
91.
Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S, et al. Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol. 2011;42(11):1667–755.PubMed
92.
Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43(8):1300–7.PubMed
93.
Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res. 2014;20(17):4584–97.PubMedPubMedCentral
94.
Theisen ER, Pishas KI, Saund RS, Lessnick SL. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. 2016;7(14):17616–30.PubMedPubMedCentral
95.
Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression profiling of EWS/FLI identifies NKX22 as a critical target gene in Ewing’s sarcoma. Cancer Cell. 2006;9(5):405–16.PubMed
96.
Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One.1965; 3: 1965.
97.
Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways. PLoS ONE. 2015;10(11):e0142704.PubMedPubMedCentral
98.
Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6(30):30178–93.PubMedPubMedCentral
99.
Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes Ewing sarcoma growth. Can Res. 2012;72:4494–503.
100.
Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, et al. EWS/ ETS fusions activate telomerase in Ewing’s tumors. Cancer Res. 2003;63(23):8338–444.PubMed
101.
Ambatia SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, et al. Moore Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol Oncol. 2014;8(2):323–36.
102.
Yu H, Ge Y, Guo L, Huang L. Potential approaches to the treatment of Ewing’s sarcoma. Oncotarget. 2017;8(3):5523–39.PubMed
103.
Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing’s sarcoma cells. Biochem Biophys Res Commun. 2010;402:129–34.PubMedPubMedCentral
104.
Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, et al. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene. 2014;33:3927–38.PubMed
105.
Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996;35:13303–9.PubMed
106.
Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13:145–53.PubMedPubMedCentral
107.
Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with Anti-IGF signaling agents. Clin Cancer Res. 2015;21(6):1373–82.PubMed
108.
Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, et al. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res. 2016;76(22):6657–68.PubMedPubMedCentral
109.
Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, et al. A phase I/II trial and pharmacokineticstudy of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80(3):645–52.PubMedPubMedCentral
110.
Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M. Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor. Clin Cancer Res. 2016;22(16):4105–18.PubMedPubMedCentral
111.
Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, et al. Combinatorial drug screening identifies Ewing sarcoma–specific sensitivities. Mol Cancer Ther. 2017;16(1):88–101.PubMed
112.
Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 1996;56(20):4570–4.PubMed
113.
Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998;58(18):4127–31.PubMed
114.
Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272(49):30822–7.PubMed
115.
Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH. Inhibition of the insulin-like growth factor i receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther. 2010;9(5):1396–407.PubMed
116.
Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011;56(4):595–603.PubMed
117.
Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010;54(7):921–6.PubMedPubMedCentral
118.
Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D. Lollini PL preclinical invivo studyof new insulin-like growth factor-I receptor specific inhibitor in Ewing’s sarcoma. Clin Cancer Res. 2007;13(4):1322–30.PubMed
119.
Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014;120(16):2448–566.PubMedPubMedCentral
120.
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(3):256–62.PubMed
121.
Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29(34):4534–40.PubMedPubMedCentral
122.
123.
Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) Inhibitors: response/resistance signatures. PLoS ONE. 2011;6(4):e18424.PubMedPubMedCentral
124.
Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, et al. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol. 2012;26:1603–16.PubMedPubMedCentral
125.
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012;18:2625–31.PubMed
126.
Macaulay VM, Middleton MR, Eckhardt SG, Juergens RA, Stephens AW, Poondru S, McCarthy SP, Gadgeel SM. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulinlike growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J Clin Oncol. 2011;29:3098.
127.
Kolb EA, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011;56:595–603.PubMed
128.
Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006;12:3532–40.PubMed
129.
Soldatenkov VA, Trofimova IN, Rouzaut A, McDermott F, Dritschilo A, Notario V. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1. Oncogene. 2002;21:2890–5.PubMed
130.
Prasad SC, Thraves PJ, Bhatia KG, Smulson ME, Dritschilo A. Enhanced poly (adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res. 1990;50:38–433.PubMed
131.
Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, et al. Combinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing's sarcoma. PLoS ONE. 2015;10(10):e0140988.PubMedPubMedCentral
132.
Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014;9(3):829–41.PubMedPubMedCentral
133.
Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer. 2014;61(1):145–60.PubMed
134.
Engert F, Schneider C, Weiβ LM, Probst M, Fulda S. PARP inhibitors sensitize Ewing sarcoma cells to Temozolomide-induced apoptosis via the mitocondrial pathway. Mol Cancer Ther. 2015;14(12):2818–30.PubMed
135.
Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015;21(4):819–32.PubMed
136.
Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813.PubMedPubMedCentral
137.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen G-M, Sevillano V. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget. 2015;6(22):18875–90.PubMedPubMedCentral
138.
Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, et al. Combining poly(ADP-ribose) polymerase 1 (PARP-1) inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther. 2013;12(11):2591–600.PubMed
139.
Tanaka A, Weinel S, Nagy N, O'Driscoll M, Lai-Cheong JE, Kulp-Shorten CL, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. Am J Hum Genet. 2012;90:511–7.PubMedPubMedCentral
140.
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene induced DNA damage model for cancer development. Science. 2008;319(5868):1352–5.PubMed
141.
Nieto-Soler M, Morgado-Palacin I, Lafarga V, Lecona E, Murga M, Callen E. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget. 2016;7(37):58759–67.PubMedPubMedCentral
142.
Robertson KD, Jones PA. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene. 1999;18:3810–20.PubMed
143.
Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375:503–6.PubMed
144.
Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 1995;375:506–10.PubMed
145.
Lin YC, Diccianni MB, Kim Y, Lin HH, Lee CH, Lin RJ, et al. Human p16-gamma, a novel transcriptional variant of p16 (INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression. Oncogene. 2007;26:7017–27.PubMed
146.
Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98:859–69.PubMed
147.
Perez M, Muñoz-Galván S, Jiménez-García MP, Marín JJ, Carnero A. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget. 2015;6(38):40557–74.PubMedPubMedCentral
148.
Hu HM, Zielinska-Kwiatkowska A, Munro K, Wilcox J, Wu DY, Yang L, Chansky HA, et al. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing’s sarcoma cells. J Orthop Res. 2008;26(6):886–93.PubMed
149.
Schwentner R, Papamarkou T, Kauer MO, Stathopoulos V, Yang F, Bilke S. EWS-FLI1 employs an E2F switch to drive target gene Expression. Nucleic Acids Res. 2015;43(5):2780–9.PubMedPubMedCentral
150.
Lillian M. Guenther, Neekesh V. Dharia, Linda Ross, Amy S. Conway, Amanda L. Robichaud, Alanna J. Church, RajarshiGuha, Mindy I. Davis, Gabriela Alexe, Jaume Mora, Federica Piccioni and Kimberly Stegmaier. Abstract 1629: Targeting resistance mechanisms to CDK4/6 inhibitors in Ewing sarcoma with an IGF1R inhibitor drug combination strategy. AACR Annual Meeting 2018; April 14–18, 2018; Chicago, IL.
151.
Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James AW, et al. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing’s sarcoma patient-derived orthotopicxenograft (PDOX) nude-mouse model. Oncotarget. 2016;7(30):47556–64.PubMedPubMedCentral
152.
Sand LG, Szuhai K, Hogendoorn PC. Sequencing overview of Ewing sarcoma: a journey across genomic, epigenomic and transcriptomic landscapes. Int J Mol Sci. 2015;16:16176–215.PubMedPubMedCentral
153.
Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, et al. Novel secondary somatic mutations in Ewingʼs sarcoma and desmoplastic small round cell tumors. PLoS ONE. 2014;9(8):e93676.PubMedPubMedCentral
154.
Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E. Preclinical evaluation of vemurafenib as therapy for BRAFV600E mutated sarcomas. Int J Mol Sci. 2018;19:969.PubMedCentral
155.
Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–78.PubMed
156.
Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J ClinOncol. 2003;21(10):1952–60.
157.
Bozzi F, Tamborini E, Negri T, Pastore E, Ferrari A, Luksch R, et al. Evidence for activation of KIT, PDGFRa, and PDGFRb receptors in the Ewing sarcoma family of tumors. Cancer. 2007;109(8):1638–45.PubMed
158.
Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E. Combined antiproliferative activity of imatinibmesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol. 2007;29(2):126–31.PubMed
159.
Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA. Phase II clinical trial of imatinibmesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010;30(2):547–52.PubMed
160.
Kumar R, Sankineani S, Rastogi S, Prakash S, Bakhshi S, Sharma MC, et al. Expression of vascular endothelial growth factor in Ewing’s sarcoma. Int Orthop. 2012;36:1669–722.PubMedPubMedCentral
161.
Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature. Angiogenesis. 2008;11:257–67.PubMedPubMedCentral
162.
Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res. 2007;13:4867–73.PubMed
163.
Ackermann M, Morse BA, Delventhal V, Carvajal IM, Konerding MA. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis. 2012;15(4):685–95.PubMed
164.
Fox E, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010;28:5174–81.PubMedPubMedCentral
165.
Winter GE, Rix U, Lissat A, Stukalov A, Müllner MK, Bennett KL, et al. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of aurora kinases A and B. Mol Cancer Ther. 2011;10(10):1846–56.PubMed
166.
Mossé YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, et al. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children’s Oncology Group Phase I Consortium study. Clin Cancer Res. 2012;18:6058–64.PubMedPubMedCentral
167.
Seethalakshmi Hariharan, Doris A. Phelps, Peter JH. Role of STAT3 in pediatric sarcoma cell lines. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016; 76: 1128.
168.
Jiang Y, Ludwig J, Janku F. Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev. 2015;41(5):391–400.PubMedPubMedCentral
169.
Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, et al. Suppression of deacetylase SIRT1 mediates tumor suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res. 2014;74(22):6578–88.PubMed
170.
Lawlor ER, Sorensen PH. Twenty years on what do we really know about Ewing sarcoma and what is the path forward. Crit Rev Oncog. 2015;20:155–71.PubMedPubMedCentral
171.
Davis KL, Fox E, Reid JM, Liu X, Minard CG, Weigel B, et al. ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors a COG study. J Clin Oncolournal Clin Oncol. 2017;35(15):10526–10526.
172.
173.
Vornicova O, Bar-Sela G. Investigational therapies for Ewing sarcoma: a search without a clear finding. Expert Opin Investig Drugs. 2016;25(6):679–86.PubMed
Metadata
Title
Precision medicine in Ewing sarcoma: a translational point of view
Authors
P. Gargallo
A. Juan
Y. Yáñez
S. Dolz
V. Segura
V. Castel
A. Cañete
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02298-7

Other articles of this Issue 9/2020

Clinical and Translational Oncology 9/2020 Go to the issue

Research Article

A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer

Research Article

Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression

Review Article

Genomic profiling in oncology clinical practice

Research Article

Hypofractionated volumetric modulated arc therapy (VMAT) for fragile patients with oesophageal cancer

Research Article

Suppressive role of Viola odorata extract on malignant characters of mammosphere-derived breast cancer stem cells

Research Article

RNF213 suppresses carcinogenesis in glioblastoma by affecting MAPK/JNK signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits